These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 21829508)
1. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508 [TBL] [Abstract][Full Text] [Related]
2. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136 [TBL] [Abstract][Full Text] [Related]
3. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132 [TBL] [Abstract][Full Text] [Related]
4. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Imamura Y; Morikawa T; Liao X; Lochhead P; Kuchiba A; Yamauchi M; Qian ZR; Nishihara R; Meyerhardt JA; Haigis KM; Fuchs CS; Ogino S Clin Cancer Res; 2012 Sep; 18(17):4753-63. PubMed ID: 22753589 [TBL] [Abstract][Full Text] [Related]
5. Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. Cohen SA; Turner EH; Beightol MB; Jacobson A; Gooley TA; Salipante SJ; Haraldsdottir S; Smith C; Scroggins S; Tait JF; Grady WM; Lin EH; Cohn DE; Goodfellow PJ; Arnold MW; de la Chapelle A; Pearlman R; Hampel H; Pritchard CC Gastroenterology; 2016 Sep; 151(3):440-447.e1. PubMed ID: 27302833 [TBL] [Abstract][Full Text] [Related]
6. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Emile JF; Diamond EL; Hélias-Rodzewicz Z; Cohen-Aubart F; Charlotte F; Hyman DM; Kim E; Rampal R; Patel M; Ganzel C; Aumann S; Faucher G; Le Gall C; Leroy K; Colombat M; Kahn JE; Trad S; Nizard P; Donadieu J; Taly V; Amoura Z; Abdel-Wahab O; Haroche J Blood; 2014 Nov; 124(19):3016-9. PubMed ID: 25150293 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. Palomba G; Colombino M; Contu A; Massidda B; Baldino G; Pazzola A; Ionta M; Capelli F; Trova V; Sedda T; Sanna G; Tanda F; Budroni M; ; Palmieri G; Cossu A; Contu M; Cuccu A; Farris A; Macciò A; Mameli G; Olmeo N; Ortu S; Petretto E; Pusceddu V; Virdis L J Transl Med; 2012 Aug; 10():178. PubMed ID: 22931052 [TBL] [Abstract][Full Text] [Related]
8. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231 [TBL] [Abstract][Full Text] [Related]
9. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. Berg M; Danielsen SA; Ahlquist T; Merok MA; Ågesen TH; Vatn MH; Mala T; Sjo OH; Bakka A; Moberg I; Fetveit T; Mathisen Ø; Husby A; Sandvik O; Nesbakken A; Thiis-Evensen E; Lothe RA PLoS One; 2010 Nov; 5(11):e13978. PubMed ID: 21103049 [TBL] [Abstract][Full Text] [Related]
10. El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Bajjou T; Sekhsokh Y; Benmokhtar S; Jafari M; Baba W; Oukabli M; El Annaz H; Abi R; Tagajdid MR; El Kochri S; Lahlou IA; Ameziane El Hassani R; Ennibi K Cancer Control; 2024; 31():10732748241262179. PubMed ID: 38875469 [TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas. Myers MB; Banda M; McKim KL; Wang Y; Powell MJ; Parsons BL Neoplasia; 2016 Apr; 18(4):253-63. PubMed ID: 27108388 [TBL] [Abstract][Full Text] [Related]
12. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. Shigaki H; Baba Y; Watanabe M; Miyake K; Murata A; Iwagami S; Ishimoto T; Iwatsuki M; Yoshida N; Baba H Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S485-91. PubMed ID: 23274581 [TBL] [Abstract][Full Text] [Related]
13. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY; J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418 [TBL] [Abstract][Full Text] [Related]
14. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Couraud S; Vaca-Paniagua F; Villar S; Oliver J; Schuster T; Blanché H; Girard N; Trédaniel J; Guilleminault L; Gervais R; Prim N; Vincent M; Margery J; Larivé S; Foucher P; Duvert B; Vallee M; Le Calvez-Kelm F; McKay J; Missy P; Morin F; Zalcman G; Olivier M; Souquet PJ; Clin Cancer Res; 2014 Sep; 20(17):4613-24. PubMed ID: 25013125 [TBL] [Abstract][Full Text] [Related]
15. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204 [TBL] [Abstract][Full Text] [Related]
16. Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer. Wu JB; Li XJ; Liu H; Liu YJ; Liu XP Biomed Rep; 2023 Dec; 19(6):104. PubMed ID: 38025833 [TBL] [Abstract][Full Text] [Related]
17. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. Di Nicolantonio F; Arena S; Tabernero J; Grosso S; Molinari F; Macarulla T; Russo M; Cancelliere C; Zecchin D; Mazzucchelli L; Sasazuki T; Shirasawa S; Geuna M; Frattini M; Baselga J; Gallicchio M; Biffo S; Bardelli A J Clin Invest; 2010 Aug; 120(8):2858-66. PubMed ID: 20664172 [TBL] [Abstract][Full Text] [Related]
18. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056 [TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer. Deb S; Do H; Byrne D; Jene N; ; Dobrovic A; Fox SB Breast Cancer Res; 2013; 15(4):R69. PubMed ID: 23971979 [TBL] [Abstract][Full Text] [Related]
20. Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX® HS, a new highly sensitive assay for the MassARRAY® System. Sutton BC; Birse RT; Maggert K; Ray T; Hobbs J; Ezenekwe A; Kazmierczak J; Mosko M; Kish J; Bullock A; Shi Z; Stack MS; Irwin D PLoS One; 2017; 12(9):e0183715. PubMed ID: 28926605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]